Loading...

CTNM CONTINEUM THERAPEUTICS INC Management Changes 8-K Filing

CNTN

CTNM

CONTINEUM THERAPEUTICS INC

(CTNM)

2025 8-K

New Funding Agreement

New Equity Plan

Clinical Trial Update

Clinical Trial Update

Q3 Financial Results

Clinical Trial Results

Financial Statements

Management Changes

Board Appointment

Financial Results

Financial Results

External Links:

On May 14, 2025, Contineum Therapeutics, Inc. reported its Q1 2025 financial results and registered for selling up to $300 million in securities, including a sales agreement for $75 million in Class A common stock.

AI Assistant

CONTINEUM THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.